Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced that preclinical data and clinical development plans for its investigational candidate GB3226 will be featured ...

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent’s newest preclinical program; on-track for IND in 2026 WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced three presentations featuring bezuclastin ...

VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SAGA Metals Corp. (“SAGA” or the “Company”) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company advancing critical mineral discoveries, is strategically positioned to capitalize on the explosive growth in the uranium sector as global nuclear commitments and artificial intelligence (AI) infrastructure propel demand far beyond current supply horizons. SAGA’s Double Mer Uranium Project: Large-Tonnage Potential in Labrador A ...

Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward improved outcomes in haemophilia A, lymphoma, and multiple myeloma Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annua ...

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions for Treating LONG COVID,” covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen® (rintatolimod) for use in the treatment of Long COVID. “While AIM’s immediate and primary focus is to build upon the continued positive results from o ...

交易核心概述 - 公司于2025年11月3日宣布启动交换要约，旨在将六系列由Shell International Finance B V和BG Energy Capital plc发行的未偿付美元票据（“旧票据”）置换为由Shell Finance US Inc发行并由公司全额无条件担保的新票据[1][2] - 此次交换要约的目的是优化集团资本结构，并使债务安排与美国业务保持一致[3] - 交换对价由现金和新票据组合构成，针对在早期参与截止日期前有效投标的持有人，每1,000美元旧票据本金将获得1,000美元新票据本金和1美元现金；在此之后有效投标的持有人将获得970美元新票据本金和1美元现金[13][15][16] 交换票据具体条款 - 涉及的五系列Shell International Finance票据未偿付本金总额分别为：2028年到期3.875%票据15亿美元、2038年到期6.375%票据27.5亿美元、2040年到期5.500%票据10亿美元、2049年到期3.125%票据12.5亿美元、2051年到期3.000%票据10亿美元[4] - 涉及的一系列BG Energy Capital plc票据为2041年到期5.125%票据，未偿付本金总额为9亿美元[4] - 新票据在利率、到期日、可选赎回日期（如适用）和付息日等主要条款上与对应的旧票据基本相同，主要区别在于发行实体和担保人等[2] 交易时间与条件 - 交换要约于2025年11月3日开始，将于2025年12月3日纽约时间下午5点截止（除非延长）[11] - 为获得总对价（包含30美元新票据本金的早期参与溢价），合格持有人必须在2025年11月17日纽约时间下午5点前有效投标其旧票据[11][15] - 旧票据的投标在2025年11月17日纽约时间下午5点前可以有效撤回，此后将不可撤销[12] - 结算日预计为截止时间后的第三个工作日，即2025年12月8日（如果要约未延长）[17] 参与资格与分销限制 - 交换要约仅面向符合特定资格条件的“合格持有人”开放，包括美国的“合格机构买家”和境外非美国人士等[20][22] - 新票据未根据美国证券法注册，因此仅可通过豁免注册的交易进行发行和销售[25] - 要约及发行文件在欧洲经济区、英国、比利时、法国、意大利、香港、日本、新加坡等司法管辖区均有相应的分销限制，通常不面向零售投资者[27][28][29][31][32][35][37][38]

Vilnius, Lithuania, Nov. 03, 2025 (GLOBE NEWSWIRE) -- As at the end of October 2025, the net asset value (NAV) of SUTNTIB AB Tewox decreased to EUR 44,897,707, compared to the previously determined NAV of EUR 45,276,142 at the end of September 2025. The share price decreased to EUR 1.0725, from EUR 1.0815 at the end of September 2025. The pro-forma internal rate of return (IRR) decreased to 3.09%, compared to previously announced IRR of 3.41% at the end of September 2025. Contact person for further informat ...

Company to Meet Dealers, Distributors and Showcase Industry-Defining Clean-Tech Solutions — SOLIS Solar Tonneau and COR Portable Energy System — in SEMA’s “New Product” Evaluation Category West Seneca, New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S.-based innovator in advanced manufacturing and distributed clean energy technologies, serving both consumer and industrial markets, today announced that it will be exhibiting at the 2025 SEMA Show i ...

INDIANA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- First Commonwealth Financial Corporation (NYSE: FCF) today announced the appointment of Joseph V. DiVito Jr. to its Board of Directors, effective immediately. DiVito brings a wealth of experience in information technology, cybersecurity, regulatory compliance, data privacy, and governance, having served clients across a broad range of industries during his distinguished career. “We are pleased to welcome Joe to the First Commonwealth Board of Directors,” said ...

- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florida, December ...